[go: up one dir, main page]

SE378109B - - Google Patents

Info

Publication number
SE378109B
SE378109B SE7206644A SE664472A SE378109B SE 378109 B SE378109 B SE 378109B SE 7206644 A SE7206644 A SE 7206644A SE 664472 A SE664472 A SE 664472A SE 378109 B SE378109 B SE 378109B
Authority
SE
Sweden
Application number
SE7206644A
Inventor
R L Brattsand
K G Claeson
Af Ekenstam B Thuresson
B A Thalen
Original Assignee
Bofors Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20269234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE378109(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SE7206644A priority Critical patent/SE378109B/xx
Application filed by Bofors Ab filed Critical Bofors Ab
Priority to IL42155A priority patent/IL42155A/en
Priority to ZA732955A priority patent/ZA732955B/xx
Priority to AU55253/73A priority patent/AU487812B2/en
Priority to DE2323215A priority patent/DE2323215C3/de
Priority to CY1013A priority patent/CY1013A/xx
Priority to GB2219473A priority patent/GB1429922A/en
Priority to ES414673A priority patent/ES414673A1/es
Priority to FI731542A priority patent/FI50631C/fi
Priority to US360051A priority patent/US3929768A/en
Priority to YU1291/73A priority patent/YU35896B/xx
Priority to CH699973A priority patent/CH595400A5/xx
Priority to DD170888A priority patent/DD104295A5/xx
Priority to DK277273AA priority patent/DK134783B/da
Priority to FR7318125A priority patent/FR2185405B1/fr
Priority to PL1973162650A priority patent/PL87765B1/pl
Priority to NLAANVRAGE7306978,A priority patent/NL177493C/xx
Priority to SU1923451A priority patent/SU470954A3/ru
Priority to NO2059/73A priority patent/NO139640C/no
Priority to CS3590A priority patent/CS178129B2/cs
Priority to HUBO1438A priority patent/HU166680B/hu
Priority to AT436573A priority patent/AT328630B/de
Priority to BE131270A priority patent/BE799727A/xx
Priority to CA171,785A priority patent/CA1002938A/en
Priority to JP5623373A priority patent/JPS5521760B2/ja
Publication of SE378109B publication Critical patent/SE378109B/xx
Priority to US05/629,389 priority patent/US3983233A/en
Priority to KE2970A priority patent/KE2970A/xx
Priority to HK491/79A priority patent/HK49179A/xx
Priority to NL930025C priority patent/NL930025I1/nl
Priority to NO1994013C priority patent/NO1994013I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE7206644A 1972-05-19 1972-05-19 SE378109B (da)

Priority Applications (30)

Application Number Priority Date Filing Date Title
SE7206644A SE378109B (da) 1972-05-19 1972-05-19
IL42155A IL42155A (en) 1972-05-19 1973-05-01 16alpha,17alpha-alkylidenedioxy-11beta,21-dihydroxy-pregna-1,4-diene-3,20-diones their manufacture and preparations containing same
ZA732955A ZA732955B (en) 1972-05-19 1973-05-01 New steroids,processes for their manufacture and preparations containing same
AU55253/73A AU487812B2 (en) 1972-05-19 1973-05-04 New Steroids, processes for their manufacture and preparations containing same
DE2323215A DE2323215C3 (de) 1972-05-19 1973-05-09 Pregna-l,4-dien-ll-ol-3,20-dione, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
CY1013A CY1013A (en) 1972-05-19 1973-05-09 Steroid acetals, processes for their manufacture and preparations containing them
GB2219473A GB1429922A (en) 1972-05-19 1973-05-09 Steroid acetals processes for their manufacture and preparations containing them
ES414673A ES414673A1 (es) 1972-05-19 1973-05-11 Procedimiento para preparar esteroides.
US360051A US3929768A (en) 1972-05-19 1973-05-14 Steroids, processes for their manufacture and preparations containing same
FI731542A FI50631C (fi) 1972-05-19 1973-05-14 Menetelmä pregnadieenijohdannaisten valmistamiseksi.
YU1291/73A YU35896B (en) 1972-05-19 1973-05-16 Process for obtaining steroids
CH699973A CH595400A5 (da) 1972-05-19 1973-05-16
DD170888A DD104295A5 (da) 1972-05-19 1973-05-17
DK277273AA DK134783B (da) 1972-05-19 1973-05-17 Analogifremgangsmåde til fremstilling af 16alfa,17alfa-alkylidendioxypregna-1,4-dien-11beta,21-diol-3,20-dioner.
PL1973162650A PL87765B1 (da) 1972-05-19 1973-05-18
FR7318125A FR2185405B1 (da) 1972-05-19 1973-05-18
CA171,785A CA1002938A (en) 1972-05-19 1973-05-18 Steroids, processes for their manufacture and preparations containing same
NLAANVRAGE7306978,A NL177493C (nl) 1972-05-19 1973-05-18 Werkwijze voor de bereiding van steroiden en werkwijze ter bereiding van een farmaceutisch preparaat tegen ontstekingen.
SU1923451A SU470954A3 (ru) 1972-05-19 1973-05-18 Способ получени производных кортикостероидов
NO2059/73A NO139640C (no) 1972-05-19 1973-05-18 Analogifremgangsmaate for fremstilling av fysiologisk virksomme 16alfa,17alfa-alkylidendioksypregna-1,4-dien-3,20-dioner
CS3590A CS178129B2 (da) 1972-05-19 1973-05-18
HUBO1438A HU166680B (da) 1972-05-19 1973-05-18
AT436573A AT328630B (de) 1972-05-19 1973-05-18 Verfahren zur herstellung neuer steroide
BE131270A BE799727A (fr) 1972-05-19 1973-05-18 Nouveaux steroides physiologiquement actifs, et procede pour leur preparation.
JP5623373A JPS5521760B2 (da) 1972-05-19 1973-05-19
US05/629,389 US3983233A (en) 1972-05-19 1975-11-06 Compositions and method of treating with stereoisomeric mixtures of 2-unsymmetrical 16,17-methylenedioxy steroids
KE2970A KE2970A (en) 1972-05-19 1979-06-20 New steriod acetals, process for their manufacture and preparations containing them
HK491/79A HK49179A (en) 1972-05-19 1979-07-19 New steroid acetals, processes for their manufacture and preparations containing them
NL930025C NL930025I1 (nl) 1972-05-19 1993-04-13 Werkwijze voor de bereiding van steroïden en werkwijze ter bereiding van een farmaceutisch preparaattegen ontstekingen
NO1994013C NO1994013I1 (no) 1972-05-19 1994-08-31 Budenosid/ 16¿, 17¿-alkyldendioksypregna-1,4-dien-3,20-dioner

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206644A SE378109B (da) 1972-05-19 1972-05-19

Publications (1)

Publication Number Publication Date
SE378109B true SE378109B (da) 1975-08-18

Family

ID=20269234

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7206644A SE378109B (da) 1972-05-19 1972-05-19

Country Status (26)

Country Link
US (2) US3929768A (da)
JP (1) JPS5521760B2 (da)
AT (1) AT328630B (da)
BE (1) BE799727A (da)
CA (1) CA1002938A (da)
CH (1) CH595400A5 (da)
CS (1) CS178129B2 (da)
CY (1) CY1013A (da)
DD (1) DD104295A5 (da)
DE (1) DE2323215C3 (da)
DK (1) DK134783B (da)
ES (1) ES414673A1 (da)
FI (1) FI50631C (da)
FR (1) FR2185405B1 (da)
GB (1) GB1429922A (da)
HK (1) HK49179A (da)
HU (1) HU166680B (da)
IL (1) IL42155A (da)
KE (1) KE2970A (da)
NL (2) NL177493C (da)
NO (2) NO139640C (da)
PL (1) PL87765B1 (da)
SE (1) SE378109B (da)
SU (1) SU470954A3 (da)
YU (1) YU35896B (da)
ZA (1) ZA732955B (da)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0197018A1 (en) * 1985-04-04 1986-10-08 Aktiebolaget Draco 16,17-Acetal-substituted androstane-17-beta-carboxylic-acid esters, process for their preparation and pharmaceutical compound containing them
EP0170642A3 (en) * 1984-07-30 1986-10-29 Aktiebolaget Draco Liposomes containing steroid esters
EP0232690A1 (en) * 1985-12-19 1987-08-19 Aktiebolaget Draco Novel 16,17-acetalsubstituted pregnane-21-oic acid derivatives, process for the preparation thereof and pharmaceutical preparation containing them
US5215979A (en) * 1985-12-19 1993-06-01 Aktiebolaget Draco 16,17-acetalsubstituted pregnane 21-oic acid derivatives

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004580L (sv) * 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
LV5274A3 (lv) * 1988-02-29 1993-10-10 Richter Gedeon Vegyeszet 22(R,S)-11 beta,21-dihidroksi-16 alpha,17-butilidenbisoksipregna-1,4-dien-3,20-diona iegusanas panemiens
HU203769B (en) * 1989-03-09 1991-09-30 Richter Gedeon Vegyeszet Process for producing new steroide derivatives and pharmaceutical compositions containing them
SE8903219D0 (sv) * 1989-10-02 1989-10-02 Astra Ab Process for the manufacture of budesonide
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US5888995A (en) * 1991-02-04 1999-03-30 Astra Aktiebolag Steroid esters
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
FR2675146A1 (fr) * 1991-04-10 1992-10-16 Roussel Uclaf Nouveaux derives sterouides de la pregna-1,4-diene-3,20-dione, leur preparation, leur application a la preparation de derives 16,17-methylene dioxy substitues et nouveaux intermediaires.
MD24B1 (ro) * 1991-07-09 1994-05-31 Parfumerii Si Cosmetice Vioric Compozitie de substante odorante
LT3695B (en) 1991-11-18 1996-02-26 Dineika Raimundas Arnas Folded roof
CZ288032B6 (cs) * 1991-12-18 2001-04-11 Aktiebolaget Astra Farmaceutický prostředek pro podání inhalací
HUT72442A (en) * 1992-12-24 1996-04-29 Rhone Poulenc Rorer Ltd Steroids condensed with heteroring containing oxygene, pharmaceutical compositions containing them and processes for their production
DK0678097T3 (da) * 1993-01-08 2000-02-07 Astra Ab Hidtil ukendte colon- eller ileumspecifikke steroidderivater
RU2132854C1 (ru) 1993-04-02 1999-07-10 Бик Гульден Ломберг Хемише Фабрик ГмбХ Производные преднизолона, способ их получения и лекарственное средство
GB9423919D0 (en) * 1994-11-26 1995-01-11 Rhone Poulenc Rorer Ltd Chemical process
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
DE29717252U1 (de) * 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
BR0010708A (pt) 1999-05-04 2002-02-19 Strakan Ltd Glicosìdeos androgênicos e atividade androgênica dos mesmos
GB0009613D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US20040235811A1 (en) * 2002-10-08 2004-11-25 Sepracor Inc. Fatty acid modified forms of glucocorticoids
JP2006523674A (ja) * 2003-04-18 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 慢性閉塞性肺疾患（ｃｏｐｄ）のための組合せ治療法
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US7825147B2 (en) * 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US7750151B2 (en) 2004-04-09 2010-07-06 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
WO2007045980A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
EP1948164A1 (en) 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Pharmaceutical compositions of muscarinic receptor antagonists
JP2009512733A (ja) * 2005-11-02 2009-03-26 シコール インコーポレイティド シクレソニドの改良された製造法
AR059216A1 (es) 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
CN101528691B (zh) 2006-08-22 2014-11-26 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
AU2007298549A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101674820B (zh) 2006-12-26 2013-09-25 药品循环公司 在联合治疗中应用组蛋白脱乙酰酶抑制剂并监测生物标志物的方法
CA2674436C (en) 2007-01-10 2012-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP1958639A1 (en) 2007-02-14 2008-08-20 Polichem S.A. Use of chitosans for the treatment of nail inflammatory diseases
US10201490B2 (en) 2007-02-14 2019-02-12 Polichem Sa Use of chitosans for the treatment of nail inflammatory diseases
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
WO2008111009A1 (en) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
HRP20120361T1 (hr) * 2007-03-14 2012-05-31 Ranbaxy Laboratories Limited DERIVATI PIRAZOLO[3,4-b]PIRIDINA KAO INHIBITORI FOSFODIESTERAZE
EP2170076B1 (en) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090082319A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched budesonide
WO2009045539A2 (en) * 2007-10-05 2009-04-09 Nektar Therapeutics Al, Corporation Oligomer-corticosteroid conjugates
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
WO2009112557A2 (en) * 2008-03-13 2009-09-17 Farmabios S.P.A. Process for the preparation of pregnane derivatives
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
CN101279997B (zh) * 2008-05-29 2011-08-24 鲁南制药集团股份有限公司 布地奈德的一种制备方法
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
PL3111926T3 (pl) * 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
BR122022005637B1 (pt) 2009-10-01 2023-03-07 Adare Pharmaceuticals, Inc Composição farmacêutica líquida não aquosa
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
WO2011093812A2 (en) 2010-01-28 2011-08-04 Mahmut Bilgic Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
US9260417B2 (en) 2010-02-08 2016-02-16 Amitech Therapeutic Solutions, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
CN101863952B (zh) * 2010-04-30 2013-04-17 湖北葛店人福药业有限责任公司 布地奈德的制备方法
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
HRP20191232T1 (hr) 2010-08-17 2019-11-01 Sirna Therapeutics Inc Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
DK2632472T3 (da) 2010-10-29 2018-03-19 Sirna Therapeutics Inc Rna-interferensmedieret hæmning af genekspression ved anvendelse af korte interfererende nukleinsyrer (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
AU2012245455A1 (en) 2011-04-21 2013-10-31 Merck Sharp & Dohme Corp. Insulin-Like Growth Factor-1 Receptor inhibitors
CA2845806C (en) 2011-09-13 2019-06-11 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013109210A1 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising budesonide
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CN103421075B (zh) * 2012-05-16 2017-07-28 上海特化医药科技有限公司 孕烷衍生物16,17‑缩醛(酮)的制备方法
US20150165037A1 (en) 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
WO2014007781A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
BR112015003729A2 (pt) 2012-08-24 2018-06-05 Univ Texas composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
PE20160155A1 (es) 2013-05-22 2016-04-01 Pearl Therapeutics Inc Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10233210B2 (en) 2015-01-30 2019-03-19 Coral Drugs Pvt. Ltd. Process for preparation of glucocorticoid steroids
EP3475275B1 (en) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US10711032B2 (en) 2016-11-08 2020-07-14 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
WO2018213077A1 (en) 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
US12134631B2 (en) 2017-11-07 2024-11-05 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3086926A1 (en) 2018-01-08 2019-07-11 Regeneron Pharmaceuticals, Inc. Steroids and antibody-conjugates thereof
MX2020011546A (es) 2018-05-09 2021-01-29 Regeneron Pharma Anticuerpos anti-msr1 y metodos de uso de los mismos.
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
CN112805006B (zh) 2018-08-07 2024-09-24 默沙东有限责任公司 Prmt5抑制剂
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US20230108114A1 (en) 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors
WO2021126731A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CR20240064A (es) 2021-07-09 2024-09-02 Astrazeneca Pharmaceuticals Lp Composiciones, métodos y sistemas para la administración de fármacos en aerosol
US20250057764A1 (en) 2021-12-20 2025-02-20 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
AU2023336062A1 (en) 2022-09-02 2025-03-13 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
CN120417935A (zh) 2022-10-25 2025-08-01 默沙东有限责任公司 依喜替康衍生的adc接头-载荷及其药物组合物和用途
AU2023397331A1 (en) 2022-12-14 2025-06-26 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) * 1964-03-24 Chioacyl
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US2990401A (en) * 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae
JPS4843910A (da) * 1971-10-08 1973-06-25

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170642A3 (en) * 1984-07-30 1986-10-29 Aktiebolaget Draco Liposomes containing steroid esters
US4693999A (en) * 1984-07-30 1987-09-15 Aktiebolaget Draco Liposomes containing steroid esters
EP0197018A1 (en) * 1985-04-04 1986-10-08 Aktiebolaget Draco 16,17-Acetal-substituted androstane-17-beta-carboxylic-acid esters, process for their preparation and pharmaceutical compound containing them
EP0355859A1 (en) * 1985-04-04 1990-02-28 Aktiebolaget Draco Process for the preparation of intermediates for 11-beta,16-alpha,17-alpha,21-tetrahydroxypregna-3,20-dione 16-alpha,17-alpha-acetals and 21-esters thereof
US4950659A (en) * 1985-04-04 1990-08-21 Aktiebolaget Draco 16,17-acetalsubstituted androstane-17β-carboxylic acid esters prossessing high binding affinity to the glucocorticosteroid receptor
EP0232690A1 (en) * 1985-12-19 1987-08-19 Aktiebolaget Draco Novel 16,17-acetalsubstituted pregnane-21-oic acid derivatives, process for the preparation thereof and pharmaceutical preparation containing them
US5215979A (en) * 1985-12-19 1993-06-01 Aktiebolaget Draco 16,17-acetalsubstituted pregnane 21-oic acid derivatives

Also Published As

Publication number Publication date
FI50631C (fi) 1976-05-10
PL87765B1 (da) 1976-07-31
NL177493C (nl) 1985-10-01
CS178129B2 (da) 1977-08-31
KE2970A (en) 1979-07-20
JPS5521760B2 (da) 1980-06-12
HK49179A (en) 1979-07-27
YU129173A (en) 1981-02-28
NL930025I1 (nl) 1993-06-01
AU5525373A (en) 1974-11-07
JPS4941378A (da) 1974-04-18
NL177493B (nl) 1985-05-01
DK134783B (da) 1977-01-17
AT328630B (de) 1976-03-25
ZA732955B (en) 1974-04-24
DD104295A5 (da) 1974-03-05
DK134783C (da) 1977-06-06
CH595400A5 (da) 1978-02-15
US3983233A (en) 1976-09-28
FR2185405B1 (da) 1976-12-31
YU35896B (en) 1981-08-31
DE2323215B2 (de) 1977-08-11
BE799727A (fr) 1973-09-17
CA1002938A (en) 1977-01-04
US3929768A (en) 1975-12-30
CY1013A (en) 1979-11-23
NO139640B (no) 1979-01-08
IL42155A (en) 1977-06-30
IL42155A0 (en) 1973-07-30
DE2323215C3 (de) 1978-03-30
FR2185405A1 (da) 1974-01-04
GB1429922A (en) 1976-03-31
ATA436573A (de) 1975-06-15
SU470954A3 (ru) 1975-05-15
NO139640C (no) 1979-04-18
NL7306978A (da) 1973-11-21
NO1994013I1 (no) 1994-08-31
HU166680B (da) 1975-05-28
ES414673A1 (es) 1976-07-01
DE2323215A1 (de) 1973-11-29
FI50631B (da) 1976-02-02

Similar Documents

Publication Publication Date Title
FR2185405A1 (da)
CS156341B1 (da)
CS156895B1 (da)
CS156799B1 (da)
CS157332B1 (da)
CS156988B1 (da)
CS156798B1 (da)
CS156978B1 (da)
CS156386B1 (da)
CS156908B1 (da)
CS149972B1 (da)
CS157561B1 (da)
CS157562B1 (da)
CS155946B1 (da)
CS156912B1 (da)
CS155632B1 (da)
CS155450B1 (da)
CS154549B1 (da)
CS154541B1 (da)
CS151841B1 (da)
CH565791A5 (da)
CH570289A5 (da)
CH586513A5 (da)
CH587273A5 (da)
CH587815A5 (da)